Targeting the EGFR signalling pathway in metastatic colorectal cancer.
Lancet Gastroenterol Hepatol
; 9(7): 664-676, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38697174
ABSTRACT
Epidermal growth factor receptor (EGFR) and its activated downstream signalling pathways play a crucial role in colorectal cancer development and progression. After four decades of preclinical, translational, and clinical research, it has been shown that blocking the EGFR signalling pathway at different molecular levels represents a fundamental therapeutic strategy for patients with metastatic colorectal cancer. Nevertheless, the efficacy of molecularly targeted therapies is inescapably limited by the insurgence of mechanisms of acquired cancer cell resistance. Thus, in the era of precision medicine, a deeper understanding of the complex molecular landscape of metastatic colorectal cancer is required to deliver the best treatment choices to all patients. Major efforts are currently ongoing to improve patient selection, improve the efficacy of available treatments targeting the EGFR pathway, and develop novel combination strategies to overcome therapy resistance within the continuum of care of metastatic colorectal cancer.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Transducción de Señal
/
Terapia Molecular Dirigida
/
Receptores ErbB
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Lancet Gastroenterol Hepatol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia